The Role of APOA-I in Alzheimer’s Disease: Bridging Peripheral Tissues and the Central Nervous System

The Role of APOA-I in Alzheimer’s Disease: Bridging Peripheral Tissues and the Central Nervous System

Lipid metabolism disorders represent a significant risk factor for the pathogenesis of Alzheimer’s disease (AD). Apolipoprotein E (APOE) has been regarded as a pivotal regulator of lipid homeostasis in the central nervous system (CNS), with polymorphic alleles identified as genetic risk factors for...

Full description

Saved in:

Bibliographic Details
Main Authors:	Guanfeng Xie, Gege Jiang, Liqin Huang, Shangqi Sun, Yuwei Wan, Fang Li, Bingjie Wu, Ying Zhang, Xiaoyi Li, Bingwan Xiong, Jing Xiong
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Pharmaceuticals
Subjects:	Alzheimer’s disease apolipoprotein A1 amyloid beta peptide lipid metabolism high-density lipoprotein
Online Access:	https://www.mdpi.com/1424-8247/18/6/790
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effect of Amyloid Beta on Cholesterol Metabolism-Correlated microRNAs in Primary Cultured Astrocytes of C57BL/6J Mice: A Focus on CYP46A1 and APOE Genes
by: Bahar Jaberian Asl, et al.
Published: (2024-11-01)

Serum and urine apolipoprotien A1 (ApoA1) as biomarkers in bladder cancer
by: Farhan Hussien Khalaf, et al.
Published: (2024-06-01)

Apolipoprotein E dysfunction in Alzheimer’s disease: a study on miRNA regulation, glial markers, and amyloid pathology
by: Printha Wijesinghe, et al.
Published: (2024-12-01)

HDL‐Apolipoprotein in Alzheimer's Disease Revisited: From Periphery to CNS
by: Yihong Huang, et al.
Published: (2025-04-01)

Associations of Serum Lipid Traits With Fracture and Osteoporosis: A Prospective Cohort Study From the UK Biobank
by: Xi Xiong, et al.
Published: (2024-12-01)

Why testing and diagnosis for Alzheimer's disease are mission critical
by: Brent W. Beasley
Published: (2025-04-01)

Apolipoprotein B gene expression and regulation in relation to Alzheimer’s disease pathophysiology
by: Gabriel Aumont-Rodrigue, et al.
Published: (2024-11-01)

Catalpol alleviates amyloid- generation and neuronal oxidative stress injury via activating the Keap1-Nrf2/ARE signaling pathway in the immortalized lymphocytes from patients with late-onset Alzheimer’s disease and SKNMC cells co-culture model
by: Caixia Xiang, et al.
Published: (2024-12-01)

Potential Roles of Hypoxia-Inducible Factor-1 in Alzheimer’s Disease: Beneficial or Detrimental?
by: Tsu-Kung Lin, et al.
Published: (2024-11-01)

Lipidopathy disrupts peripheral and central amyloid clearance in Alzheimer's disease: Where are our knowledge
by: Shahram Darabi, et al.
Published: (2025-06-01)

Inspecting the potential of thymol as a therapeutic agent for treating Alzheimer's disease
by: Muhammad Waleed Imran, et al.
Published: (2024-10-01)

Cerebral inflammatory amyloid angiopathy: response to treatment
by: João Roberto Ribeiro Pimenta, et al.
Published: (2025-08-01)

Relación entre tipo y cantidad de carbohidratos dietarios con el perfil lipídico y ApoB100 en adultos
by: Martha Guerra, et al.
Published: (2010-08-01)

Alterations in LDL and HDL after an ischemic stroke associated with carotid atherosclerosis are reversed after 1 year‡
by: Núria Puig, et al.
Published: (2025-02-01)

A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies
by: Heike Hering, et al.
Published: (2025-08-01)

Beneficial Influence of Agomelatine Treatment on Behavioral Impairments in AΒ-Induced Rat Model of Alzheimer’s Disease
by: Kalina Ilieva, et al.
Published: (2020-12-01)

Latest Indian Guidelines for Dyslipidemia Management: A Biochemist’s Perspective
by: Shalini Gupta
Published: (2024-12-01)

Editorial: Alzheimer’s disease
by: Ryszard Pluta
Published: (2025-06-01)

GABA Signaling in Spatial Memory changes in Animal Model of Alzheimer’s disease
by: Bahareh Tavakoli-Far, et al.
Published: (2024-08-01)

The Potential Mechanism and the Role of Antioxidants in Mitigating Oxidative Stress in Alzheimer’s Disease
by: Rayees Ahmad Naik, et al.
Published: (2025-02-01)

Specific Binding of Alzheimer’s Abeta Peptide Fibrils to Single Walled Carbon Nanotubes
by: Steingrimur Stefansson, et al.
Published: (2012-10-01)

Immune cell responses to amyloid-beta proteins: What is the extent and implications of amyloid-beta induced cytotoxicity in microglial cells and peripheral blood mononuclear cells?
by: Cao, A.
Published: (2017-07-01)

The mechanism underlying streptozotocin injection for the development of a nontransgenic Alzheimer's disease animal model
by: Nurina Titisari, et al.
Published: (2025-02-01)

Use of Model‐Based Meta‐Analysis to Inform the Design of Early Clinical Trials of Anti‐Amyloid Beta Therapies in Alzheimer's Disease
by: Sagar S. Bachhav, et al.
Published: (2025-07-01)

Blood essential trace elements and Alzheimer’s disease biomarkers in midlife
by: Xin Wang, et al.
Published: (2025-05-01)

Amyloid-β Inhibiting Peptides: An Innovative Strategy for Alzheimer’s Disease Treatment
by: Sajjad Molavipordanjani, et al.
Published: (2023-11-01)

MicroRNA-615-3p decreases apo B expression in human liver cells
by: Abulaish Ansari, et al.
Published: (2024-10-01)

Oral nicotinic acid administration effect on lipids, thyroid hormones, and oxidative stress in intact adult dogs
by: Nooshin Derakhshandeh, et al.
Published: (2025-03-01)

Lipoprotein (a) Screening, and What's Next?
by: Pasławska Anna, et al.
Published: (2024-12-01)

Associations of Plasma and CSF Osteocalcin Levels With CSF ATN Biomarkers and Cognitive Functions in Alzheimer's Disease
by: Xian‐Le Bu, et al.
Published: (2025-07-01)

Novel targets for the treatment and prevention of Alzheimer's disease in the European population, inspiration from amyloid beta and tau protein
by: Xifeng Wang, et al.
Published: (2024-10-01)

Promotion of neuroinflammation in select hippocampal regions in a mouse model of perimenopausal Alzheimer’s disease
by: Roberta Marongiu, et al.
Published: (2025-05-01)

Autophagy and Alzheimer’s Disease: Mechanisms and Impact Beyond the Brain
by: Zaw Myo Hein, et al.
Published: (2025-06-01)

Neuroprotective effect of ranolazine in mice's model of Alzheimer's disease
by: Mariam H. Sadiq, et al.
Published: (2024-06-01)

Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
by: Taha basit Ameen, et al.
Published: (2025-05-01)

Unleashing light's healing power: an overview of photobiomodulation for Alzheimer's treatment
by: Aakash Ramanishankar, et al.
Published: (2024-01-01)

A Review Article on Oxidative Stress Markers F2-Isoprostanes and Presenilin-1 in Alzheimer’s Disease
by: Dilip Raj Timalsina, et al.
Published: (2025-05-01)

Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease
by: Sha Sha, et al.
Published: (2026-02-01)

The past, present and future of Alzheimer's disease – part 1: the past
by: Ricardo Nitrini
Published: (2023-12-01)

Pathology and Treatments of Alzheimer’s Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 Diabetes
by: Hidekatsu Yanai, et al.
Published: (2024-12-01)